Equities

Genedrive PLC

Genedrive PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)5.75
  • Today's Change-0.375 / -6.12%
  • Shares traded2.23m
  • 1 Year change-73.26%
  • Beta-0.9815
Data delayed at least 20 minutes, as of Apr 25 2024 11:42 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

genedrive plc is a United Kingdom-based patient molecular diagnostics company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company offers products, including Genedrive MT-RNR1 ID Kit and Genedrive COV19-ID Kit. Genedrive MT-RNR1 ID Kit is a rapid genetic test in an emergency neonatal care setting. It has developed tests for the detection of Antibiotic Induced Hearing Loss in neonates, confirmation of hepatitis c virus (HCV), infection prior to drug administration, pathogen detection of biological military threats, and a point-of-care for COVID-19 detection system for us in areas such as healthcare, workplace screening, travel requirements, or confirmation of antigen tests.

  • Revenue in GBP (TTM)272.00k
  • Net income in GBP-5.00m
  • Incorporated2007
  • Employees43.00
  • Location
    Genedrive PLC48 Grafton StreetMANCHESTER M13 9XXUnited KingdomGBR
  • Phone+44 161 989 0245
  • Fax+44 161 989 0262
  • Websitehttp://www.genedriveplc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medclair Invest AB2.94m-205.40k7.48m14.00--2.0336.902.55-0.0314-0.03140.50800.60560.65041.369.952,846,643.00-4.55-11.20-5.40-12.9562.1469.51-6.99-26.941.08-7.160.0078--60.1352.1444.27--24.59--
Telesis Bio Inc22.07m-39.33m7.76m137.00--40.59--0.3516-1.64-1.640.92160.98250.36253.394.65200,795.60-62.89---73.37--61.62---173.49--3.22-34.090.1577--0.2697---1.14------
Phoslock Environmental Technologies Ltd1.51m-5.15m8.14m40.00--1.64--5.41-0.0158-0.01580.00460.01530.16132.163.55---55.13---66.97---81.68---341.76--2.82-405.840.051---51.35---184.79------
Bio-View Ltd7.38m81.30k8.25m--89.511.3417.651.120.00320.00320.25680.21630.82892.335.48--0.91323.451.234.5761.4858.711.104.202.15--0.1138--19.296.58-34.75--8.77--
Titan Logix Corp3.78m-340.69k8.38m----0.8519--2.22-0.0204-0.02040.2190.58690.3572.376.94---3.220.6038-3.350.626147.2652.34-9.022.1617.45--0.045--43.576.69-92.63---22.16--
Polarean Imaging PLC273.89k-11.51m8.43m28.00--0.838--30.76-0.054-0.0540.00130.04650.01530.11340.19719,781.90-64.22-59.80-72.25-68.3839.6559.23-4,201.18-574.074.66--0.0225---12.86-3.540.7877--30.60--
Genedrive PLC272.00k-5.00m8.77m43.00--4.98--32.23-0.0509-0.05090.00280.01230.0658--1.606,325.58-120.84-97.55-197.86-128.51-----1,837.50-797.031.36-7.490.0789--12.24-50.95-10.16--16.72--
Scanway SA1.09m-438.12k9.03m59.00--2.72--8.30-1.72-1.724.2613.01------93,081.70--------44.16---40.29--2.48-150.660.00--------------
TOKYO KOKI CO LTD17.03m488.41k9.95m136.0020.351.2015.510.584113.2713.27462.45224.310.81022.183.6124,247,490.002.322.684.204.4335.9730.312.872.701.3018.580.33570.00-24.37-7.56-674.98---50.86--
Quarta-Rad Inc407.84k35.70k10.05m0.00282.6931.86276.6124.650.00280.00280.03240.02510.70743.0014.74--6.19-0.007111.98-0.015536.0732.788.75-0.00410.7347--0.00---53.81-10.96205.14------
PZ Cormay SA16.28m-890.32k10.17m225.00--0.9296183.450.6247-0.0534-0.05340.97650.65620.83961.935.38365,444.40-4.64-12.12-7.19-17.1840.8739.19-5.53-16.500.7141--0.0811---3.673.3335.43---3.97--
Holmarc Opto-Mechatronics Ltd-962.91m-962.91m10.64m--------------------------------------------------38.12--129.49------
Data as of Apr 25 2024. Currency figures normalised to Genedrive PLC's reporting currency: UK Pound GBX

Institutional shareholders

16.65%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Asset Management Ltd.as of 01 Jan 20225.48m3.96%
Jarvis Investment Management Ltd.as of 14 Jun 20232.95m2.13%
IG Markets Ltd.as of 01 Jan 20222.74m1.98%
Rathbones Investment Management Ltd.as of 01 Jan 20222.35m1.69%
HSBC Global Asset Management (UK) Ltd.as of 01 Jan 20222.21m1.59%
BGF Investment Management Ltd.as of 05 Feb 20211.91m1.38%
Walker Crips Investment Management Ltd.as of 01 Jan 20221.90m1.37%
M&G Investment Management Ltd.as of 05 Feb 20201.76m1.27%
Unicorn Asset Management Ltd.as of 31 Mar 20241.15m0.83%
Peel Hunt LLPas of 01 Jan 2022617.00k0.45%
More ▼
Data from 31 Dec 2023 - 12 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.